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Abstract
Background: Due to their unique property to migrate to pathological lesions, stem cells are used as a delivery vehicle for
therapeutic genes to tumors, especially for glioma. It is critically important to track the movement, localization, engraftment
efficiency and functional capability or expression of transgenes of selected cell populations following transplantation. The
purposes of this study were to investigate whether 1) intravenously administered, genetically transformed cord blood
derived EPCs can carry human sodium iodide symporter (hNIS) to the sites of tumors in rat orthotopic model of human
glioma and express transgene products, and 2) whether accumulation of these administered EPCs can be tracked by
different in vivo imaging modalities.
Methods and Results: Collected EPCs were cultured and transduced to carry hNIS. Cellular viability, differential capacity and
Tc-99m uptake were determined. Five to ten million EPCs were intravenously administered and Tc-99-SPECT images were
acquired on day 8, to determine the accumulation of EPCs and expression of transgenes (increase activity of Tc-99m) in the
tumors. Immunohistochemistry was performed to determine endothelial cell markers and hNIS positive cells in the tumors.
Transduced EPCs were also magnetically labeled and accumulation of cells was confirmed by MRI and histochemistry. SPECT
analysis showed increased activity of Tc-99m in the tumors that received transduced EPCs, indicative of the expression of
transgene (hNIS). Activity of Tc-99m in the tumors was also dependent on the number of administered transduced EPCs.
MRI showed the accumulation of magnetically labeled EPCs. Immunohistochemical analysis showed iron and hNIS positive
and, human CD31 and vWF positive cells in the tumors.
Conclusion: EPC was able to carry and express hNIS in glioma following IV administration. SPECT detected migration of EPCs
and expression of the hNIS gene. EPCs can be used as gene carrier/delivery system for glioma therapy as well as imaging
probes.
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Introduction
Due to their unique property to migrate to pathological lesions,
stem cells are considered to be used as a delivery vehicle for
therapeutic genes to tumors, especially for glioma [1,2]. Investi-
gators have used neural and mesenchymal stem cells as vehicles for
delivering cytotoxic or therapeutic genes [1,3,4]. These cells were
administered either locally or systemically. Schichor et al. have
pointed out that cells should meet the following criteria to be used
as gene delivery vehicles in glioma: 1) cells should be used as an
autologous transplant system in each glioma patient to avoid
potential immune response, and 2) within human brain paren-
chyma, cells should exhibit active motility directed toward glioma
tissues [4]. Endothelial progenitor cells (EPCs), a subpopulation of
pluripotent hematopoietic stem cells (HSC), showed active
migration and incorporation into neovasculature of glioma when
administered locally or systemically [5,6]. Based on EPCs’
characteristics, it is possible to use these cells as carriers or
delivery vehicles for therapeutic genes to tumors or glioma, which
can be administered either systemically or locally. Moreover, these
EPCs can be collected from patients’ peripheral blood.
In order to evaluate efficacy and appropriateness of cell based
therapy, it becomes critically important to track the movement,
localization, engraftment efficiency, and functional capability or
expression of transgenes of selected cell populations following
transplantation. The available techniques are suboptimal in this
regard. For instance, in vivo fluorescent or bioluminescent molecular
and/or cellular imaging techniques lack the resolution necessary to
localize the sites of active cell migration and accumulation. Although
nuclear medicine techniques can be used to track the radioisotope
tagged administered cells, associated radiation injury and short half-
life of usable radioisotopes are their drawbacks. Recently, we have
created superparamagnetic iron oxide (SPIO)-transfection agent
complexes using two FDA approved agents; Ferumoxides (Fe) and
Protamine sulfate (Pro), to label a broad range of mammalian cells.
The labeled cells can then be used as probes to localize physiological
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for high-resolution images in a clinical setting [7,8]. Cells labeled with
the ferumoxides-protamine sulfate (FePro) complexes can be imaged
at clinically relevant MRI fields using standard imaging techniques
and also at higher fields typical for animal experiments. We and
others have shown that labeling cells with ferumoxides did not alter
viability and functional capability of cells or differential capacity of
stem cells [9].
Human sodium iodide symporter (hNIS) is an intrinsic trans-
membrane glycoprotein that mediates transport of iodide into the
thyroid follicular cells [10,11]. This transport system also
transports Tc-99m pertechnetate (Tc-99m) that can be imaged
by gamma camera [12,13]. Visualization and quantification of Tc-
99m activity at the site of interest (following administration of
transduced cells) would provide the evidence of homing, viability,
and expression of exogenous hNIS gene in transduced cells. The in
vivo use of genetically modified EPC requires that duration and
level of expression of the encoded transgene to be monitored.
Ideally, the monitoring system should also be able to monitor cell
homing and viability, and demonstrate the persistence of site-
specific gene expression in vivo. MRI can be used with iron-based
contrast to detect homing of administered stem cells with high
resolution [5,6] but MRI may not be useful to monitor the
functional activity of the cells. Although MRI has been used to
monitor the expression of ferritin in transduced implanted cells;
expression of ferritin is not considered to be a target for treatment
[14]. Expression of hNIS with resultant Tc-99m uptake can
conveniently be imaged with single photon emission computed
tomography (SPECT) or gamma camera that can determine hNIS
expression in vivo, which will indicate the effectiveness of EPC to
carry gene of interest to the sites of tumors.
The purposes of this study were to determine whether 1)
intravenously administered genetically transformed cord blood
derived EPC can carry hNIS to the sites of tumors in rat
orthotopic model of human glioma and express transgene
products, and 2) whether accumulation of these administered
EPC can be tracked by in vivo MRI and the expression of hNIS can
be determined by in vivo Tc-99m SPECT. Ultimate goal was to
determine whether in future, EPC could be used as gene carrier/
delivery system for glioma therapy.
Materials and Methods
Ethics statement
Human cord blood was collected under Henry Ford Health
System Institutional Review Board (IRB) approved protocol
(protocol number 3287). Collection of cord blood was anonymous
and patients’ profile was not documented. Ethics committee (IRB
committee) approved waiver of consent. All production of
lentivectors and transduction of stem cells were performed under
Henry Ford Health System Institutional Recombinant DNA and
Biosafety Committee (IRDBC) approved protocol (protocol
number 2008.12). Animal experiments described in the manu-
script were approved by our animal care and user committee at
Henry Ford Health System (protocol number 753 and 988)
according to the guideline and policies of office of laboratory
animal welfare (OLAW) and public health service, National
Institutes of Health. All the experiments were performed
according to the approved protocol.
CD133+ endothelial progenitor cells (EPCs)
Freshly collected and cultured CD34
+/CD133
+ EPCs were
used for transduction and magnetic labeling. CD34
+/CD133
+
EPCs were collected from the human cord blood. In brief, cord
blood mononuclear cell population was generated by Ficoll
gradient centrifugation and was enriched for CD34
+/CD133
+
cells by immunomagnetic positive selection using the MidiMACS
system (Miltenyi, Auburn, CA) according to the manufacturer’s
protocol. Freshly prepared CD34
+/CD133
+ cells were incubated
in stem cell basal media supplemented with 40 ng/ml of stem cell
factor (SCF), 40 ng/ml of fms-like tyrosine kinase receptor-3
ligand (FLT3L) and 10 ng/ml of thrombopoietin (TPO) (all from
CellGenix, IL). Initially cells were suspended in media at 1610
6
per ml and grown in 5% CO2/95% air at 37uC in humidified
atmosphere, with fresh media added every third day. The cells
were propagated for 7–10 days. To confirm the purity of the
culture isolated from cord blood, flowcytometry was done at day 1
to assess the levels of progenitor markers CD133, CD34,
hematopoietic CD45, CD117 and CD14 markers, and CD20
and CD3 that are commonly expressed on B and T cells,
respectively. More than 90% cells were CD34
+/CD133
+.
Development of hNIS gene carrying lentivector
To construct pCDH-hNIS vector, the hNIS gene was amplified
using NISCMVF1 and NISCMVR1 primers. The NISCMVF1
primer was a 27-mer forward primer with an XbaI site
(59ACTTCTAGAGCCACCATGGAGGCC-39). NISCMVR1
was a 32-mer reverse primer with an EcoRI site
(59CGCGAATTCTCAGAGGTTTGTCTCCTGCTG-39). The
restriction enzyme recognition sites are in italics. A 25 ml polymer
chain reaction (PCR) sample was prepared according to MBI
Fermantas using pNIS vector (a gift from Dr. Barton) as a
template. PCR was carried out using Mastercycler (Eppendorf,
Germany), with following program: 95uC for 5 min to denature
and then amplification was carried out over 30 cycles of 94uC for
1 min, 55uC for 1 min and 72uC for 1 min; and after the last cycle
the reaction was held at 72uC for 10 min. Amplified hNIS gene was
digested by XbaI and EcoRI, followed by ligation into the
corresponding sites on plasmid plent-CMV (SBI, USA). The
ligated DNA was transformed into E. coli cells by the heat-shock
method. Ampicillin-resistant transformants were then selected,
followed by plasmid extraction and restriction digestion analyses.
Lentivirus production
293TN cells (SBI, USA) were seeded at a density of 1.6610
8 per
100 mm tissue culture dish and transiently transfected with
lentivirus transfer vectors (pCDH-hNIS) and three viral packaging
plasmids (pPACKH1-GAG, pPACKH1-Rev, pVSV-G) (SBI,
USA) according to the manufacturer protocol. After 16 h the
media was replaced with Dulbecco’s modified essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
20 mM HEPES, pH 7.05 (Sigma). The supernatants were
harvested at 48 and 72 hours and further concentrated using 56
PEG solutions (SBI, USA). Concentrated virus was stored at
280uc prior to use. Titers of concentrated lentiviral vector were
determined using Global UltraRapid Lentiviral Titer Kit (SBI,
USA). Lentivector titers were in the range of 10
9 transducing units
(TU)/ml.
Optimization of viral dose
To determine the optimal viral dose, cells (1610
6 cells) were
infected at 37uC, 5% CO2 with increasing dose of viral particles
(1000, 2000 and 5000 viral particles per cell) in 200 ml. After one
hour, 1 ml of fresh media was added and transferred to a 6-well
plate and further incubated for 48 hours. Viability and transgene
expression were determined by trypan blue dye exclusion test and
Tc-99m uptake assay, respectively.
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To test Tc-99m uptake ability of transduced cells, 10 mCi of Tc-
99m (Mallinckrodt, USA) was added to 1610
6 cells (in serum free
media) and incubated at 37uC for 30 min. Following incubation,
cells were washed twice with 5 ml of phosphate buffered saline
(PBS) and cell associated Tc-99m activity in the resultant cell
pellets was measured using gamma counter (Wizard 1420,
PerkinElmer, USA). Tc-99m uptake was also determined following
magnetic labeling of transduced EPC.
Transduction of EPCs with lentiviral vector containing
hNIS gene
Following optimization all subsequent transduction of EPC was
performed by maintaining viral dose of 2000 particles per cell.
Lentiviral vector carrying the hNIS gene was used to transduce
cells. Expression of the gene product was under CMV (cytomeg-
alovirus) promoter (Figure 1A). During transduction cells were
maintained at a concentration of 10 million per ml for initial
1 hour and then diluted 610 with complete stem cell media.
Transduction efficiency was determined on day 3 and following
magnetic labeling by Tc-99m uptake assay. These transgenic cells
were magnetically labeled on day 4 after transduction using FePro.
Labeling of cells with ferumoxides-protamine sulfate
(FePro) complex
Cells were labeled according to our recently published updated
method [8]. In brief, ferumoxides (Fe) (Feridex IVH, Berlex
Laboratories, Inc, Wayne, New Jersey, 100 mg/ml) were directly
added to the cell suspension in serum free media and then
protamine sulfate (Pro) (American Pharmaceuticals Partner Inc.
Schaumburg, IL, 3 mg/ml) was added. The FePro complexes were
formed in the cell suspension. After 15 minutes of incubation in
serum free media, an equal volume of complete media (containing
different cytokines) was added to the cell suspension and further
incubated for 4 hours. The cells were then collected, washed with
sterile PBS and resuspended at the specific concentration for
injection. Labeling efficiency and intracellular iron concentration
were also determined as described in our previous reports [8,15].
Cellular viability, proliferation of Fe-Pro labeled and/or
transduced EPCs
Cells were washed at least twice with sterile PBS and
resuspended in PBS at the concentration of 3610
7 cells/ml. A
small aliquot of cells was mixed with trypan blue dye and checked
under a microscope to determine cell viability. Specific number of
control (non-transduced non-FePro labeled), non-transduced
FePro labeled, and transduced FePro labeled, cells were placed
back into culture flasks and total numbers of cells in the cultures
were monitored up to day 15.
Differential capacity of FE-Pro labeled and/or transduced
EPCs
Differentiation potential of EPCs transduced with lentivirus-
hNIS (labeled or unlabeled) as well as control EPCs was assessed.
EPCs were suspended in stem cell basal media supplemented with
2% fetal bovine serum (FBS) and 2 ng/ml of Vascular Endothelial
Growth Factor (VEGF) and plated on glass cover slips coated with
fibronectin at the concentration of 2610
5/cm
2. Cells were allowed
to differentiate for 2 weeks. Old media was replenished with fresh
media on every 3 days and cells were monitored by microscopy for
morphological changes associated with differentiation. After 2
weeks, differentiated transduced EPCs were analyzed by immu-
Figure 1. Vector design, Tc-99m uptake assay, viability and proliferation following FePro labeling. (A) Map of the lentivector carrying
hNIS. Effect of viral doses (VD) on viability (B) and Tc-99m uptake (C) showed that at 5000 viral particles per cells only about 35% cells were viable,
although increased Tc-99m activity was observed at this dose. However, based on viability and Tc-99m uptake subsequent experiments were
performed with a dose of 2000 viral particles per cell. Magnetic labeling showed decreased proliferation on day 3 compared to unlabeled cells,
however, proliferation rate recovered on later days (D). *=p,0.05.
doi:10.1371/journal.pone.0030310.g001
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markers. The cells were analyzed using endothelial specific
antibodies such as mouse anti-human anti CD31, rabbit anti-
human anti von Willebrand Factor (vWF) (DakoCytomation) and
rabbit anti-human anti CD309 (VEGFR2 or KDR) (Thermo
Scientifics). Texas Red or FITC conjugated secondary antibodies
(Jackson ImmunoResearch, Inc) were used. Negative control
samples were treated with secondary antibodies only. All the
antibodies were used according to supplier’s directions. To
visualize nuclei, cells were counterstained with DAPI nuclear
stain. Cells were analyzed by fluorescent microscopy. Fluorescent
images were acquired with a fixed exposure time (10 sec for FITC
and 20 sec for Texas Red labeled cells).
Human glioma cells (U-251)
Human glioma cells (U-251, gift from Dr. Steve Brown, HFH)
were cultured in 75 cm
2 tissue culture flasks with Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% FBS,
penicillin (100 IU/mL), and streptomycin (100 mg/mL) until they
were 80–90% confluent. Then, the cells were collected by
trypsinization, washed and centrifuged to make a cell suspension
of 4610
5cells/5 ml.
Animal model
Athymic nude rats 6–8 weeks of age and 150–170 g of weight
(Charles River Laboratory, Inc.) were anesthetized by intraperi-
toneal injection using ketamin/xylazine mixture (100 mg/kg
ketamine, 10 mg/kg xylazine) and were placed on a stereotactic
head holder. The tumor was implanted according to our reported
methods [16]. In brief, after exposing the skull and drilling a hole
3 mm to the right and 1 mm anterior to the bregma, a 10 mL
micro-syringe fitted with 26 s gauge-needle containing tumor cells
(4610
5)i n5ml was lowered to the depth of 4 mm, then raised to
the depth of 3 mm. The U251 cells were injected stepwise at a rate
of 0.5 mL/30 sec until the entire volume had been injected.
During and after the injection, careful note was made of any reflux
from the injection site. Two to three minutes after completing the
injection the syringe was withdrawn in a stepwise manner. The
surgical hole was sealed with a bone wax, cleaned, and the
overlying skin was sutured. There were a total of four groups of
animals. A total of 26 animals were included in this study;
however, due to lack of optimal tumor size and missing SPECT
studies 5 animals were excluded. There were at least 4 animals in
each group (4–6 animals per group).
Intravenous administration of hNIS transduced and FePro
labeled EPCs
Five to ten million of EPCs were intravenously administered in
rats bearing human glioma through tail vein 14 days after tumor
implantation. All animals underwent pre-injection MRI. Four
different groups of animals received different doses of cells as
follows: 1) 5610
6 of FePro labeled non-transduced (LNTG) EPCs
(5 animals as negative control for Tc-99m SPECT), 2) 5610
6 of
non-FePro labeled transduced (NLTG) EPCs (4 animals, negative
control for MRI), 3) 5610
6 of FePro labeled transduced (LTG)
EPCs (6 animals), and 4) 5610
6 of FePro labeled transduced plus
5610
6 of non-FePro labeled transduced (LTG+NLTG) EPCs (6
animals). Different number of transduced EPCs (groups 2 or 3 vs
4) was used to determine whether higher number would allow
better detection of transgene expression by Tc-99m SPECT.
FePro labeled and unlabeled transduced EPCs (group 2 vs 3) were
used to determine whether FePro labeling would decrease the
migration and transgene expression in the tumors. Following
administration of EPCs, rats underwent MRI and Tc-99m SPECT
to determine the migration and accumulation of FePro labeled
and transduced cells carrying hNIS, on days 7 and 8, respectively.
Timing of MRI was based on our previous experiences where we
have shown that most of the migration and incorporation of
administered EPCs were dependent on the tumor size and varied
from 3–14 days following IV administration [5,6]. We have
selected date of SPECT studies after MRI because the
transportation of radioactive animals to other building was
restricted by IACUC. Recently we have shown that transduced
EPCs can express the transgene products even after 38 days [17].
Magnetic Resonance Imaging (MRI) study
To prepare each rat for MRI studies, the rat was anesthetized
with 1.5–2.0% isoflurane in oxygen. Rats were secured to a
customized cradle. Rats were studied by MRI 1 day before and 7
days after IV administration of EPCs. MR images were obtained
with a 3.0 Tesla clinical system (Signa Excite, GE health) using
50 mm diameter small animal imaging coil (Litzcage small animal
imaging system, Doty Scientific Inc, Columbia, SC). Three
dimensional (3D) isotropic FIESTA images were acquired. The
following parameters were used to acquire the images. For
isotropic 3D FIESTA images: TR=11.4 ms, TE=5.6 ms, using a
2006200 matrix, FOV=60 mm, and NEX=2, effective slice
thickness was 0.3 mm.
MR image analysis
Circular ROIs were drawn on the tumor sections encompassing
as much tumor area as possible and signal intensity histogram
profiles as well as average signal intensity were recorded. Animals
from FePro labeled transduced (LTG) and FePro non-labeled
transduced (NLTG) groups were included in the analysis.
SPECT Study
Within 24 hours after last MRI, animals underwent SPECT
studies using Tc-99m to determine the status of genetically
transformed cells at the sites of tumors. Animals were anesthetized
using ketamine/xylazine (100/10 mg/kg) and received 1 mCi of
Tc-99m through tail vein injection in a volume of 1–2 ml.
60 minutes after Tc-99m injection, animals were wrapped with
padded sheet to keep them warm and placed in the imaging holder
under anesthesia. SPECT was acquired with a dedicated PRISM
3000 gamma camera fitted with mutli-pinhole rat collimator, 360
degree rotation with 36 degree increments, 180 sec per projection,
using 2566256 matrices with a field of view of 466 cm. The total
time required for acquiring SPECT was about 31 minutes.
Euthanasia and histological analysis
Immediately after SPECT, animals were euthanized and
perfused with saline and paraformaldehyde to dissect and further
analyze tissues by histology. The animals were euthanized with
100 mg/kg of pentobarbital administration (intravenous or
intraperitoneal). The radioactive fluids were collected and
contained in a shielded area to decay. Whole brains were collected
for histochemical determination of iron labeled cells using Prussian
blue (PB) staining and endothelial cells markers such as CD31 and
vWF using human specific antibodies (DakoCytomation, USA).
Expression of hNIS in accumulated cells was determined by
staining with anti-hNIS antibody (Genetex, TX, USA).
Supplemental studies
To determine the distribution of IV administered EPCs in
different organs at different time points, animals bearing glioma
EPCs as Gene Delivery and Imaging Probes
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underwent SPECT studies 1 to 72 hours following administration.
To differentiate between the activity of In-111 and that of In-111
labeled cells on SPECT images, animals bearing glioma that
received In-111-oxine alone also underwent SPECT studies.
Data analysis
All data are expressed as mean 6 standard deviation. The data
were analyzed with two-way analysis of variance and the
significance level was set at 0.05.
Results
Vector design, Tc-99m uptake assay, viability and
proliferation following magnetic labeling
Figure 1A shows the vector design. We have used CMV as
promoter for the expression of hNIS, based on our previous
experiments, where we have used four different promoters (CMV,
EF-1, UBC and SV40) [17]. We determined the successful
transduction of cells by Tc-99m uptake. For optimizing the
transduction efficiency without compromising the cell viability it is
important to determine the cell to viral dose. Cells were incubated
with different doses of viral particles and then the cell associated
Tc-99m activity and cell viability were determined. Based on the
viability and Tc-99m uptake, it was determined that the dose of
2000 viral particles per cells was optimal for transduction of EPCs
(Figure 1B, 1C). We used this ratio in all subsequent studies.
Following transduction, EPCs were magnetically labeled using
FePro and used as MRI probes to monitor the cell migration and
accumulation at the sites of implanted glioma in rat brain. As
described in our previous studies, we achieved labeling efficiency
of almost 100% [8] that resulted in successful detection of iron
labeled cells by in vivo MRI. However, it is also important to
determine the proliferation capacity of transduced cells with or
without FePro labeling. Following transduction of hNIS gene into
EPCs, significant differences were observed (day 5 and 10) in the
growth curve compared to that of non-transduced EPCs
(Figure 1D). After labeling EPCs with FePro, the same difference
was observed between non-transduced FePro labeled and hNIS
transduced FePro labeled EPCs. However, there were no
differences in cell viability determined by trypan blue dye
exclusion test (data not shown) among control and transduced
EPCs with or without FePro labeling. Altogether these results
indicated that hNIS transduction may be the cause of transient
growth retardation observed on days 5 and 10 in both non-labeled
transduced and FePro labeled transduced EPCs (although similar
pattern of growth curve was observed for all groups between days
5 to days 15). On the other hand, FePro labeled cells exhibited
significant decrease in Tc-99m uptake (10061.15% vs.
81.7868.55%, p,0.02) in transduced EPCs.
Differential capacity of transduced cells
To determine whether transduction of exogenous genes affected
the ability of non-labeled and FePro-labeled EPCs to differentiate
towards endothelial cell lineage; non-transduced non-FePro
labeled (control), transduced non-FePro labeled, and transduced
FePro labeled EPCs were cultured in endothelial cell differenti-
ating media. After 15 days the expression of mature endothelial
cell type markers, VEGFR2 (KDR) and vWF, was determined by
immunocytochemistry. No differences were observed between
control, transduced and transduced FePro labeled EPCs in their
ability to express these endothelial markers (Figure 2).
MRI and SPECT analysis
To determine the effect of transduction of exogenous gene
(hNIS) on migration and tumor incorporation of transplanted
EPCs, FePro labeled non-transduced EPCs, non-labeled trans-
duced and FePro labeled transduced EPCs were intravenously
administered to rats bearing U251 glioma that underwent MRI 1
day before and 7 days after EPCs’ administration. As expected, all
animals that received FePro labeled EPCs exhibited low signal
intensity areas on MRI that was detected along the outer regions
of the tumors, indicating accumulation of iron positive cells with
no differences observed between the animals receiving FePro
labeled non-transduced EPCs and FePro labeled hNIS transduced
EPCs (Figure 3A). The accumulation of iron positive cells was
confirmed by PB histochemical staining. Animals that received
non-FePro labeled cells did not exhibit any significant low signal
intensity areas in the tumors (Figure 3A). MRI analysis also
showed significant differences (p,0.05) in signal intensity changes
between the groups of animals that received FePro labeled and
non-labeled transduced EPCs as shown by the histogram profiles
of signal intensities (Figure 4).
To determine whether hNIS transduced EPCs expressed hNIS
transgene product after migration and incorporation into the
tumors, Tc-99m-SPECT images were obtained on day 8 after the
administration of EPCs. It was expected that if hNIS protein was
present in the tumor, Tc-99m activity would be higher compared
to the tumor of the animals that received non-transduced EPCs
due to the uptake of Tc-99m through trans-genetically encoded
and expressed hNIS trans-membrane channel. Although MRI
showed low signal intensity areas in animals that received 5610
6
of FePro labeled hNIS transduced cells, SPECT images showed
only slightly increased Tc-99m activity, which was not seen in all
animals (Figure 3A). Similarly the animals that received 5610
6 of
non-FePro labeled hNIS transduced EPCs also showed slightly
higher activity of Tc-99m in all tumor-bearing rats (Figure 3A).
To increase the signal detected by SPECT, we have administered
higher dose of hNIS transduced EPCs that included 10610
6 hNIS
transduced cells out of which only 5610
5 cells were FePro labeled
as well. This resulted in much higher activity of Tc-99m detected
in rats that received double dose of transduced EPCs (Figure 3B)
due to the higher number of cells expressing transgene hNIS
protein channel. The activity was clearly visible within the tumor
areas in all animals. Figure 5 shows Tc-99m activities in different
organs of representative glioma bearing animals that received
control and hNIS transduced EPCs. Increased Tc-99m activity
was seen in tumor and liver in animal that received hNIS
transduced EPCs, indicating the expression of hNIS in the
accumulated transduced EPCs. The activity in all other organs
was similar between the two groups of animals (control EPCs vs.
hNIS transduced EPCs). Immunohistochemistry confirmed hNIS
positive cells in and around the tumors that received hNIS
transduced EPCs and the number of detected hNIS positive cells
were higher in rats that received double dose of hNIS transduced
EPCs (10610
6 cells) compared to rats that received the dose of
5610
6 (Figure 6A). To determine whether iron labeling impaired
the expression of hNIS transgene product in administered EPCs,
same or consecutive tissue sections were stained with PB for iron
positive cells. Tumors in animals that received both, FePro labeled
and non-FePro labeled hNIS transduced EPCs showed multiple
hNIS positive cells. However, many of the iron positive cells
detected in the same area did not exhibit hNIS positivity (LGT,
Figure 6A) indicating that not all of the administered FePro
labeled hNIS transduced EPCs maintained the expression or hNIS
protein after migrating to the tumor site.
EPCs as Gene Delivery and Imaging Probes
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To determine whether FePro labeled or unlabeled hNIS
transduced EPCs incorporated into tumor angiogenesis or
vasculogenesis, sections were double stained either with vWF
and hNIS antibodies, or CD31 and hNIS antibodies. To confirm
that the source of positive signals detected by these antibodies is
from administered cells that were FePro labeled, consecutive tissue
sections were stained with PB. In both cases multiple double
positive cells were observed in the tumors (Figure 6B). The vWF
and CD31 were also seen in tumors of the animals that received
non-transduced EPCs.
Distribution of administered EPCs
Supporting information S1 shows the distribution of IV admin-
istered In-111 labeled EPCs at different time points. About 40% of
the injected cellsdistributed inthe lungs at 1 hour, which cleared very
rapidly and after 72 hours there was less than 2% of injected cells
remaining. Activity in the liver and spleen remained stable from 2 to
72 hours. When normalized to tumor volume (cm
3), there was
average of more than 2.25% of injected EPCs that migrated to brain
tumor, which indicate that about 112,500 EPCs accumulated (/cm
3
of tumor mass) in glioma after 24 hours. On the other hand
contralateral brain (CLB/cm3) showed minimum activity at 3 hours
with a washout observed at 24 and 72 hours. The distribution pattern
of In-111 labeled EPCs was different from that of In-111-oxine.
Discussion
Our results proved our hypothesis that EPCs could be used to
carry gene to the sites of interest and that the migration of EPCs
carrying gene of interest can be tracked by in vivo imaging
modalities. Low signal intensities detected by MRI enabled
tracking of administered cells while increased uptake of Tc-99m
in tumors, detected by in vivo SPECT, indicated functional
expression of transgene after incorporation of EPCs in glioma.
In that sense, EPCs can be used at the same time as probes for
MRI or SPECT and as gene carrier systems.
Importance of EPCs as gene carriers
Numerous previous publications, as well as our own reports,
indicated the important role of cord blood or peripheral blood
derived CD133
+ EPCs in neo-vasculo- as well as angiogenesis
associated with tumors or ischemic lesions [6,18,19]. Migration
and homing of exogenously administered or bone marrow
mobilized endogenous EPCs to tumor or ischemic lesions are
dependent on the expression of stromal derived factor (SDF-1)
[6,20,21]. SDF-1 is chemo-attractant for cells such as EPCs, that
express abundant CXCR4 receptors [21] and our previous work
demonstrated that exogenously administered, either peripheral
blood derived CD133
+ or cord blood derived adult CD133
+ EPCs,
targeted and migrated to the areas of tumors where HIF-1
mediated SDF-1 expression was significantly increased [6]. Here
we show that as expected, transduced EPCs carrying hNIS gene
migrated and homed to the sites of tumors. Immunohistochemistry
also indicated that these EPCs migrated and incorporated into
tumor angiogenesis/vasculogenesis that was in accordance with
now well established evidence that EPCs are involved in both
vasculogenic and angiogenic processes [18,20,22,23]. Transduced
EPCs also expressed functional gene product that resulted in
intracellular uptake of Tc-99m through trans-genetically expressed
hNIS channel which was detected by in vivo SPECT. In addition,
hNIS expression was confirmed by immunohistochemistry.
Expression of functional product by exogenously introduced gene
is extremely important and strongly depends on the promoter used
in driving that expression [17]. Previously we have demonstrated
that when viral vectors were used, EF-1 and CMV promoters were
very effective in driving the expression of exogenous genes. Here,
we have selected to use CMV as promoter because of
demonstrated sustained long-term expression of transgene in the
cells [17]. Based on our successful transduction and use of EPCs to
carry the gene to the sites of tumor, future experiments can be
designed to develop therapeutic strategies. Here we used hNIS as
reporter protein to be detected by Tc-99m SPECT, however,
expression of hNIS can also be utilized to induce cell death as
radioactive iodine (such as I-131) is actively taken up by the
transduced cells. In addition, hNIS can also act as check-and-
balance mechanism, where I-131 can be used to control unwanted
growth of transduced cells. Therefore, hNIS can be used both, as
an in vivo reporter and as a suicidal gene. Alternatively, EPCs can
be used as gene carriers for other proteins with anti-tumor effects.
For example, EPCs can be transduced with either double suicidal
genes, such as Cytosine Deaminase/herpes simplex virus-1
Figure 2. Differentiation capacity of transduced cells. Expression of endothelial markers (KDR and vWF) in FePro labeled transduced (LTG) or
non-Fepro labeled transduced (NLTG) EPCs following incubation in endothelial cell differentiation media for 15 days. All of these cells also showed
expression hNIS. None of the control EPCs showed expression of hNIS, although expression of both the markers of endothelial cell was observed.
doi:10.1371/journal.pone.0030310.g002
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express inflammatory or cytotoxic cytokines [26,27] or cyto-
chrome P4502B1 (CYP2B1) gene that is to increase intratumoral
concentrations of pro-drugs [28]. In addition, blockage of vascular
endothelial growth factor (VEGF) function using soluble vascular
endothelial growth factor receptor 1 gene can be used to inhibit
tumor growth [29,30]. Alternatively, immune agents such as
Interferon-beta (IFN-beta) genes can also be delivered using EPCs
to suppress the tumor growth [31]. However, to prevent non-
specific expression of suicidal gene products in transduced cells in
different unwanted targets, vector can be designed for conditional
expression of transgene product using tissue specific promoters.
EPCs as probes for MRI and SPECT
FePro labeling allows for EPCs’ migration to be tracked by in
vivo MRI to homing sites, implanted glioma in rats in this study.
Previously, we have reported tracking of locally or intravenously
administered EPCs detected by high strength small animal MR
Figure 3. MRI and SPECT images for tracking of administered EPCs and gene expression. (A) MRI and SPECT following
administration of 5610
6 EPCs. Pre-injection and 7 days post injection MR images of representative animals that received FePro labeled non-
transduced (LNTG, upper row), non-FePro labeled transduced (NLTG, middle row) and FePro labeled transduced (LTG, lower row) EPCs intravenously.
Note that low signal intensity areas/foci are seen in tumors that received FePro labeled cells (upper and lower rows, dotted circles) compared to the
tumor that received non-FePro labeled cells (middle row). There was slight increase in focal activity of Tc-99m (white arrows) observed in tumor areas
that received transduced EPCs (middle and lower rows). (B) MRI and SPECT following administration of 10610
6 EPCs. Pre-injection and 7 days
post injection MR images of 3 representative animals that received 5 million FePro labeled transduced (LTG) plus 5 million non-FePro labeled,
transduced (NLTG) EPCs. Note that low signal intensity areas/foci are seen in all tumors following administration of FePro labeled EPCs (dotted
circles). There was increased focal activity of Tc-99m (white arrows) observed in all tumor areas.
doi:10.1371/journal.pone.0030310.g003
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subcutaneous and intracranial tumors [5,6,32]. In this study, we
have used clinical 3 Tesla MRI systems to track intravenously
administered cord blood derived EPCs to intracranial glioma
tumor where administered EPCs exhibited accumulation at the
sites of active angiogenesis. All animals that received 5610
6 of
FePro labeled transduced or non-transduced EPCs showed areas
of low signal intensity in and around the tumor 7 days following
administration of cells. However, SPECT analysis showed a slight
increase in Tc-99m activity in tumors that received 5610
6 of
either FePro labeled or unlabeled transduced EPCs. But, when the
number of administered cells was increased to 10610
6 cells,
increase in Tc-99m activity was detected by SPECT in tumors of
all animals. These findings indicated that transplanted cell
accumulation within the tumor at the administered dose of 5
million cells, did not result in accumulation of sufficient amounts
of Tc-99m to be detected by SPECT scanning. On the other hand,
at the same dose of 5 million cells tumor accumulation of FePro
labeled transduced and non-transduced EPCs exhibited significant
change in low intensity signals detected by MRI. Based on our
previously reported FePro labeling method that ensured for almost
100% labeling efficiency [8], it was expected that at the dose of 5
million FePro labeled cells, the migrated cells would carry the iron
to the sites of interests and the number would be sufficient to be
detected by MRI. However, the same was not observed on
SPECT analysis with hNIS FePro labeled or non-labeled
transduced cells. The number of cells expressing functional hNIS
that migrated to the tumor was at least 2 times less (40%
transduction efficiency) than that of cells that contained MRI
detectable levels of FePro, and that was apparently below the
detection Tc-99m threshold of SPECT. Since transduction
efficiency was not more than 40% and the selection of transduced
cells was not performed prior to transplantation it was expected
that increasing the dose of administered cells would reach this
threshold. When the number of administered transduced cells was
increased to 10610
6, there was clear visualization of Tc-99m
activity in the tumors. Under circumstances of achieving almost
100% of transduction efficiency, both MRI and SPECT could be
considered to have exhibited similar sensitivity in detecting
migrated EPCs in the tumors. Still, it is to note that iron labeling
is much more efficient than lentivirus transduction and therefore
practical sensitivity of MRI is greater. However, hNIS gene
transduction in conjunction with SPECT analysis was used here as
a proof of principle study. When developing therapeutic and/or
Figure 4. Histogram profile of signal intensity. Signal intensity histogram from representative animals of FePro labeled transduced (LTG) (black
circles) and non-FePro labeled transduced (NLTG) groups (grey circles). Comparison of average signal intensity between two groups of animals
showed significant differences (bar graphs). Note the low signal intensity in tumors that received FePro labeled transduced (LTG) cells (n=3).
doi:10.1371/journal.pone.0030310.g004
Figure 5. Whole body SPECT images for tracking of adminis-
tered EPCs and gene expression. The distribution of Tc-99m
activities is almost identical in animals bearing tumors that received
non-transgenic (left) and transgenic EPCs, except the activities in the
tumor and liver. Animal that received transgenic EPC showed higher
activity in liver and tumor. Images are displayed in identical windows.
Note there is no activity seen in the lungs and in the tumor that
received non-transgenic EPCs (arrow, tumor).
doi:10.1371/journal.pone.0030310.g005
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imaging detection, however MRI could still be used for the
purpose of tracking and monitoring the fate of transplanted gene
transduced cells. Current methods of MRI cannot estimate the
number of incorporated magnetically labeled cells in area of
interest due to endogenous iron, hemorrhage in the tumors and
slower blood flow in the tumors. All of these will show low signal
intensity areas on T2*-weighted or FIESTA images as we have
previously reported [33]. However, if necessary to determine the
numbers of migrated cells, EPCs can be tagged with In-111 or Tc-
99m-HMPAO before injection. Our supplemental studies (sup-
porting information S1) showed that 2.25% of administered In-
111 labeled EPCs accumulated in tumor, which indicated the
accumulation of 112,500 EPCs in the tumor. Terrovitis et al [34]
have indicated that accumulation of 1610
5 of transduced cells
carrying hNIS are needed to be detected in vivo by Tc-99m
SPECT. Based on this value and considering our transduction
efficiency, at least 2% of the administered cells migrated to the
sites of tumors, which is also proven by In-111 labeled EPCs
studies.
Following IV injection, EPCs will pass through liver and spleen
where some of the administered cells may be held up. In addition,
some of the administered EPCs will also home to bone marrow.
During this migratory process all the injected EPCs that have died
are expected to be cleared by liver and spleen. Only active and
viable EPCs will migrate and accumulate at the margin of the
tumor due to the specific migratory signals, such as HIF-1a
induced SDF-1 expression [6,35]. Once at the tumor site where
vasculogenesis is the most active, injected EPCs will either be
incorporated into the tumor neovasculatures or remain idle
without incorporating into the angiogenic processes. However,
further investigations are warranted to determine the minimal
number of hNIS transduced cells needed to be detected by Tc-
99m SPECT at the site of tumors or other lesions following IV
administration.
Tracking of hNIS positive transduced stem cells and
advantage of SPECT
Investigators have used transduced stem cells and tracked them
by various in vivo imaging modalities. However, most of
investigations dealt with local administration of transduced cells
followed by in vivo imaging of the gene product by biolumines-
cence, fluorescence, SPECT or PET scanning [36,37,38].
Tracking of intravenously administered transduced cells by
nuclear medicine techniques is challenging and requires sensitive
imaging modalities, stable transduction and use of radionuclide
that will be optimal in respect to energy, half-life and cost. PET is
very sensitive imaging modality and has been widely used to track
systemically administered genetically transduced cells. One of the
most widely used reporter genes for PET imaging is wild-type
herpes simplex virus type 1 thymidine kinase (HSV1-tk) and it’s
HSV1-sr39tk mutant. This enzyme efficiently phosphorylates
Figure 6. Cytochemistry of differentiated EPCs and Immunohistochemistry. (A) hNIS and Prussian blue staining: Immunohistochem-
istry of representative sections showed hNIS (red cells, left column) and iron positive cells (brown cells, right column) in FePro labeled non-transduced
(LNTG), non-FePro labeled transduced (NLTG), FePro labeled transduced (LTG), and FePro labeled transduced plus non-FePro labeled transduced
(LTG+NLTG) groups. Note that multiple iron positive cells are seen in tumors that received FePro labeled EPCs. hNIS positive cells are seen in tumors
that received transduced EPCs. The animal that received FePro labeled non-transduced (LNTG) EPCs showed multiple iron positive cells but no hNIS
positive cells (upper row, the small red dot is due to artifact). All tumors that received transduced cells showed multiple hNIS positive cells (red cells).
The animals that received double dose of transduced EPCs (LTG+NLTG) showed more hNIS positive (red) cells than corresponding iron positive cells
(brown). PB=DAB enhanced Prussian blue. (B) Expression of human endothelial cell markers in the tumors: Both FePro labeled non-
transduced (LNTG) and FePro labeled transduced (LTG) administered EPCs showed incorporation into tumor vasculatures and expressed human
specific endothelial markers (CD31 and vWF). Note the endothelial markers positive cells are also positive for hNIS indicating functional expression of
transgenes.
doi:10.1371/journal.pone.0030310.g006
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with radio labeled reporter probes such as
124I-29-fluoro-29-deoxy-
1-b-D-b-arabinofuranosyl-5-iodouracil (FIAU),
18F-29-fluoro-
29-deoxy-1-b-D-b-arabinofuranosyl-5-ethyluracil (FEAU) and
18F-9-(4-
18F-fluoro-3-hydroxymethyl-butyl)guanine (FHBG)
[39,40,41,42]. hNIS positive cells can also be tracked with I-124,
a positron emitter [43]. However, the disadvantage of PET is its
short half-lived radionuclides with higher energy (511 keV) and
repeated scanning with high energy tracer could be detrimental to
the transduced cells. In addition dedicated radiochemistry
laboratory and cyclotron are needed, which are very expensive.
On the other hand, although less sensitive than PET, SPECT can
utilize relatively short half-lived and low energy radionuclides,
such as Tc-99m and I-123, to track hNIS transduced cells. These
radiotracers are available through vendors and are very cheap
compared to PET tracers. Moreover, PET and dedicated
radiochemistry laboratory are not widely available to molecular
imaging investigators.
Conclusion
This is the first study to report the use of cord blood derived
EPCs to carry a gene (hNIS) to the sites of glioma, and the
migration and the expression of gene products were determined by
in vivo MRI and SPECT studies, respectively. These EPCs were
used both as gene carrier and imaging probes. EPCs can be used
to deliver therapeutic genes to the sites of lesions. The use of EPCs
to carry therapeutic gene to the sites of different lesions are
underway in our laboratory.
Supporting Information
Supporting Information S1 To determine the distribution of
IV administered EPCs to different organs in tumor bearing rats,
In-111-oxine labeled EPCs were administered IV on day 21
following tumor implantation. Cells were labeled with In-111-
oxine using a standard method keeping the In-111 dose at 2–3 bq/
cell. SPECT images were obtained at different time points, from 1
hour to 72 hours. To differentiate between the activity of In-111
and that of In-111 labeled cells on SPECT images, animals
bearing glioma that received In-111-oxine alone also underwent
SPECT images were obtained at different time points. Supporting
information Figures S1 and S2 show the biodistribution of In-
111-oxine and In-111 labeled EPCs in different organs and in the
tumors.
(DOC)
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